TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
Lymphoblastic Leukemia
DRUG: Dexamethasone|DRUG: Mitoxantrone|DRUG: PEG asparaginase|DRUG: Bortezomib|DRUG: Vorinostat|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Blinatumomab|DRUG: Ziftomenib
Minimal Residual Disease, Proportion of patients who are minimal residual disease positive at the end of Induction Intensification, 5 years and 2 months
Ziftomenib Minimum safe and Biologically-Effective Dose in Combination with Chemotherapy, To determine the estimated minimum safe and biologically-effective dose of Ziftomenib in combination with chemotherapy, on the basis of observed DLTs, MRD assessments, and pharmacokinetic studies, 5 years and 6 months|Event Free Survival, To estimate the 3-year event-free survival for subjects treated on study, 8 years|Overall Survival, To estimate the 3-year overall survival for subjects treated on study, 8 years
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.